Agilex Biolabs Pty Ltd has been purchased by one of Australia’s leading healthcare companies, Healius Limited
With increasingly novel drug development programs, meaningful collection of subject samples has never been more relevant. Don’t let potential analyte instability mislead your program as it gets underway, causing costly time delays
Agilex Biolabs Congratulates VGI Health Technology Limited for successful filing of a new PCT Patent Application on Transmucosal Delivery of Tocotrienols
With the integration of leading toxicology company TetraQ into Agilex Biolabs’ service offering, Agilex Biolabs is now the only...
Meet the Scientists series - Meer Dr Jason Geue, R& D Manager at Agilex Biolabs.
Agilex Biolabs, Australia’s most experienced and technologically advanced bioanalytical laboratory and the only biolab in the region with a dedicated toxicology unit, has been selected as a finalist for the Most Successful Early Phase Research (Preclinical & Phase I) category in the Citeline Awards 2021.
https://youtu.be/dnyLFRPLEJo...
Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.
...
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials is showcasing its new $1.5m vaccine and immunobiology laboratory at BIO Asia Taiwan 2021. The facility, the most sophisticated in APAC, is designed for biotechs and pharma from around the world for advanced clinical research including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
